Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | State of the art: MDS

David Steensma • 5 Mar 2020
MDS 2020
Anemias Myelodysplastic Syndromes Lenalidomide Luspatercept

David Steensma, MD, Dana-Farber Cancer Institute, Boston, MA, discusses current treatment options for both high and low-risk myelodysplastic syndromes (MDS) patients. Dr Steensma reveals that there’s not a well-established second-line therapy, representing an unmet clinical need. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from David Steensma

2:51
MDS and Agent Orange
David Steensma • 5 Mar 2020
0:43
MDS novel agents & HMAs
David Steensma • 5 Mar 2020
0:52
Azacitidine in the treatment of MDS
David Steensma • 5 Mar 2020
1:32
Clonal hematopoiesis & MDS
David Steensma • 5 Mar 2020

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:45
A 2-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemia
Antonio Risitano • 16 Apr 2024
3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals